Long-Acting Growth Hormone Shot Proves Safe and Effective Over Four Years

A new once-weekly injection for growth hormone deficiency maintained efficacy and safety through four years of treatment, according to the REAL 3 trial. The findings could reshape how doctors manage this chronic condition, potentially reducing patient burden from frequent injections while lowering healthcare costs.

Originaltitel: Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3